Objective: Guanfacine extended release (GXR) is a selective α2A-adrenoceptor agonist that is shown to be an effective nonstimulant treatment for the symptoms of attention-deficit/hyperactivity disorder. This report documents the time course and predictors of symptom efficacy and sedation-related adverse events (AEs) that emerge during GXR treatment throughout 3 randomized, placebo-controlled, double-blind trials of the drug. Method: Analysis of data from 3 GXR clinical trials. Results: Few variables related to the study participants or their treatment regimen affects the emergence or magnitude of sedation-related AEs. The best predictor of sedation is treatment duration, with the likelihood of sedation-related AEs decreasing with increasing time on medication. Sedation-related AEs are not predicted by the actual dose a participant receives, the magnitude of any dose changes, or the relationship between dose received and the magnitude of dose changes. Rates of discontinuation because of sedation-related side effects average 6.3% for GXR-treated participants and 0.5% for placebo-treated participants across the three trials. Conclusion: These results suggest that acclimation to GXR may minimize the risk for, and magnitude of, sedation-related AEs. (J. of Att. Dis. 2010; 13(5) 532-538)
American Psychiatric Association [APA]. (2000 a). Diagnostic and statistical manual of mental disorders DSM-IV (4th ed.). Washington, DC: APA.
2.
APA. (2000b). Diagnostic and statistical manual of mental disorders DSM-IV-TR. (4th ed.), Text revision. Washington, DC : APA, 85-102.
3.
Arnsten, A.F. ( 2006). Fundamentals of attention-deficit/hyperactivity disorder: Circuits and pathways. Journal of Clinical Psychiatry , 67(suppl 8), 7-12.
4.
Arnsten, A.F.T. ( 2001). Dopaminergic and noradrenergic influences on cognitive functions mediated by prefrontal cortex. In M. V. Solanto, A. F. T. Arnsten, & F. X. Castellanos (Eds.), Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press.
5.
Arnsten, A.F., Cai, J.X., & Goldman-Rakic, P.S. (1988). The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. Journal of Neuroscience, 8, 4287-4298.
Biederman, J., Melmed, R.D., Patel, A., McBurnett, R., Konow, J., Lyne, A. et al, for the SPD503 Study Group. ( 2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121, e73-e84.
8.
Carchman, S.H., Crowe, J.T., Jr., & Wright, G.J. ( 1987). The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. Journal of Clinical Pharmacology, 27, 762-767.
9.
Chappell, P.B., Riddle, M.A., Scahill, L., Lynch, K.A., Schultz, R., Arnsten, A. et al. (1995). Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: Preliminary clinical experience. Journal of the American Academy of Child & Adolescent Psychiatry, 34, 1140-1146.
10.
Faraone, S.V., Biederman, J., Spencer, T.J., & Aleardi, M. ( 2006). Comparing the efficacy of medications for ADHD using meta-analysis. Medscape General Medicine, 8, 4.
11.
Horrigan, J.P., & Barnhill, L.J. (1995). Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. Journal of Child and Adolescent Psychopharmacology, 5, 215-223.
12.
Hunt R.D., Arnsten, A.F.T., & Asbell M.D. ( 1995). An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 34, 50-54.
13.
Jansson, C.C., Marjamaki, A., Luomala, K., Savola, J.M., Scheinin, M., & Akerman, K.E. ( 1994). Coupling of human alpha 2-adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells. European Journal of Pharmacology, 266, 165-174.
14.
Kollins, S.H., Wigal, T., Vince, B., Turnbow, J., Lopez, F.A., Brams, M. et al. (2007). Guanfacine extended release in ADHD: Safety and sleep effects. Poster presentation at the American Academy of Child and Adolescent Psychiatry 54th Annual Meeting; October 23-28, Boston, MA.
15.
Newcorn, J.H., Schulz, K., Harrison, M., DeBellis, M.D., Udarbe, J.K., & Halperin, J.M. (1998). Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatric Clinics of North America, 45, 1099-22, viii.
16.
Pliszka, S.R., Crismon, M.L., Hughes, C.W., Corners, C.K., Emslie, G.J., Jensen, P.S. et al., and the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder. ( 2006). The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 642-657.
17.
Sallee, F., McGough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman J., for the SPD503 Study Group. (2007 ). Randomized, double-blind study of guanfacine extended release for 6- to 17-year-olds with attention-deficit/hyperactivity disorder (submitted) . Journal of the American Academy of Child & Adolescent Psychiatry.
18.
Scahill, L., Chappell, P.B., Kim, Y.S., Schultz, R.T., Katsovich, L., Shepherd, E. et al. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry, 158, 1067-1074.
19.
Uhlén, S., & Wikberg J.E.S. (1991). Delineation of rat kidney α2Aand α2B-adrenoceptors with [3H]RX821002 radioligand binding: Computer modelling reveals that guanfacine is an α2A-selective compound. European Journal of Pharmacology, 202, 235-243.
20.
Vuong, Q.H. ( 1989). Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica, 57, 307-333.
